Clinical evaluation of lens culinaris agglutinin-reactive α-fetoprotein and des-γ-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States

被引:174
作者
Carr, Brian I.
Kanke, Futoshi
Wise, Margaret
Satomura, Shinji
机构
[1] Univ Pittsburgh, Med Ctr, Liver Canc Ctr, Starzl Transplantat Inst, Pittsburgh, PA 15213 USA
[2] Wako Pure Chem Ind Ltd, Diagnost Div, Osaka, Japan
[3] Wako Chem USA Inc, Diagnost Div, Richmond, VA USA
关键词
lens culinaris agglutinin-reactive fraction of alpha-fetoprotein; des-gamma-carboxy prothrombin (DCP); alpha-fetoprotein; hepatocellular carcinoma; prognosis;
D O I
10.1007/s10620-006-9541-2
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
There is no established clinical role for the lens culinaris agglutinin-reactive fraction of alpha-fetoprotein (AFP-L3%) and des-gamma-carboxy prothrombin (DCP) in the management of the U.S. hepatocellular carcinoma (HCC) patient population. In order to clarify the clinical usefulness and characteristics of AFP-L3% and DCP, a prospective study was performed on United States patients having histologically proven hepatocellular carcinoma. Ninety-nine histologically proven HCC patients, who were diagnosed with unresectable cancer between July 1999 and March 2001 at the Liver Cancer Center of the University of Pittsburgh Medical Center, were included for analysis. The sensitivity of AFP-L3%, DCP, and AFP was 61.6%, 72.7%, and 67.7%, respectively. The highest sensitivity, 85.9%, was obtained in the combination of three markers. Statistically significant differences were observed for portal vein invasion in AFP-L3% and AFP levels (P=0.0059 and P=0.0360, respectively). DCP was significantly associated with metastasis (P=0.0368). There were significant associations between AFP-L3% and AFP results and patient survival (P=0.0150 and P=0.0020, respectively). AFP-L3%, platelet count,and albumin showed a significant difference with respect to outcomes on Cox's proportional hazard model (P=0.0059, P=0.0073, and P=0.0265, respectively). The combination of AFP-L3%, DCP, and AFP was determined to be superior for detection of HCC compared with each marker alone or to other combinations. AFP-L3% was significantly related to portal vein invasion and patient outcomes and appears to be a useful prognostic marker for HCC.
引用
收藏
页码:776 / 782
页数:7
相关论文
共 51 条
[1]
Aoyagi Y, 1996, CANCER, V77, P1781
[2]
Management of hepatoceullular carcinoma [J].
Bruix, J ;
Sherman, M .
HEPATOLOGY, 2005, 42 (05) :1208-1236
[3]
Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference [J].
Bruix, J ;
Sherman, M ;
Llovet, JM ;
Beaugrand, M ;
Lencioni, R ;
Burroughs, AK ;
Christensen, E ;
Pagliaro, L ;
Colombo, M ;
Rodés, J .
JOURNAL OF HEPATOLOGY, 2001, 35 (03) :421-430
[4]
A new prognostic classification for predicting survival in patients with hepatocellular carcinoma [J].
Chevret, S ;
Trinchet, JC ;
Mathieu, D ;
Rached, AA ;
Beaugrand, M ;
Chastang, C .
JOURNAL OF HEPATOLOGY, 1999, 31 (01) :133-141
[5]
HEPATOCELLULAR-CARCINOMA IN ITALIAN PATIENTS WITH CIRRHOSIS [J].
COLOMBO, M ;
DEFRANCHIS, R ;
DELNINNO, E ;
SANGIOVANNI, A ;
DEFAZIO, C ;
TOMMASINI, M ;
DONATO, MF ;
PIVA, A ;
DICARLO, V ;
DIOGUARDI, N .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (10) :675-680
[6]
α-fetoprotein and ultrasonography screening for hepatocellular carcinoma [J].
Daniele, B ;
Bencivenga, A ;
Megna, AS ;
Tinessa, V .
GASTROENTEROLOGY, 2004, 127 (05) :S108-S112
[7]
DIAGNOSIS OF SMALL HEPATOCELLULAR-CARCINOMA - CORRELATION OF MR IMAGING AND TUMOR HISTOLOGIC-STUDIES [J].
EBARA, M ;
OHTO, M ;
WATANABE, Y ;
KIMURA, K ;
SAISHO, H ;
TSUCHIYA, Y ;
OKUDA, K ;
ARIMIZU, N ;
KONDO, F ;
IKEHIRA, H ;
FUKUDA, N ;
TATENO, Y .
RADIOLOGY, 1986, 159 (02) :371-377
[8]
Hepatocellular carcinoma: Recent trends in the United States [J].
El-Serag, HB .
GASTROENTEROLOGY, 2004, 127 (05) :S27-S34
[9]
Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States [J].
El-Serag, HB ;
Mason, AC ;
Key, C .
HEPATOLOGY, 2001, 33 (01) :62-65
[10]
Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma [J].
Fujiyama, S ;
Tanaka, M ;
Maeda, S ;
Ashihara, H ;
Hirata, R ;
Tomita, K .
ONCOLOGY, 2002, 62 :57-63